Mr. Arbuckle has served as a member of our Board since July 2019. From August 2021 to July 2025, Mr. Arbuckle was Executive Vice President and Chief Operating Officer at Vertex Pharmaceuticals Incorporated, a biopharmaceutical company, where he was responsible for the company s global commercial team, including reimbursement and access, sales, marketing, patient support, market research and other activities that supported the approved use of Vertex s cystic fibrosis medicines. Mr. Arbuckle also oversaw the Human Resources, Corporate Communications and Program and Portfolio Management functions. Prior to assuming that role, he served as Executive Vice President and Chief Commercial Officer at Vertex from September 2012 to March 2021. Prior to joining Vertex, Mr. Arbuckle held several commercial leadership positions at Amgen Inc., including leading sales and marketing efforts for Amgen Inc. s portfolio of cancer medicines, such as Aranesp , Neulasta injection and NEUPOGEN , and leading the successful launches of XGEVA injection and Nplate injection. Most recently, he served as Vice President and Regional General Manager at Amgen Inc., where he led efforts to expand the company s presence in Asia, the Middle East, and Africa. Prior to these roles, Mr. Arbuckle spent 15 years at GlaxoSmithKline plc, where he held sales and marketing roles for medicines aimed at treating metabolic, respiratory, musculoskeletal, cardiovascular and other diseases. Mr. Arbuckle serves on the boards of Alnylam Pharmaceuticals, Inc. and Praxis Precision Medicines, Inc. Mr. Arbuckle previously served as a board member of ImmunoGen, Inc. from January 2019 to February 2024. Mr. Arbuckle holds a BSc in Pharmacology and Physiology from the University of Leeds in the United Kingdom. The Board considered Mr. Arbuckle s senior executive roles at publicly-held life sciences companies, as well as his service on the boards of directors of biotechnology companies and organizations, in concluding that he is qualified to serve as a director.